Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: the life of a blockbuster; blockbusters by indication; gene therapy struggles; sun shines on AstraZeneca and GSK; and Korean ventures look to Japan.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 17 May 2024, including: the life of a blockbuster; blockbusters by indication; gene therapy struggles; sun shines on AstraZeneca PLC and GSK plc; and Korean ventures look to Japan.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "The Life Of A Blockbuster" - Scrip, 10 May, 2024.)
(Also see "Blockbusters By Indication: More Begets More" - Scrip, 13 May, 2024.)
(Also see "Gene Therapy Q1 Roundup: The Struggle Is Real" - Scrip, 9 May, 2024.)
(Also see "Stock Watch: The Sun Shines On AstraZeneca And GSK" - Scrip, 14 May, 2024.)
(Also see "Japan Looks For Role As Korean Ventures’ New Step To Global Market" - Scrip, 14 May, 2024.)